About: Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.01 (-0.74%)
ANNX NASDAQ Annexon Inc
Annexon Inc share price
Atividade de preço de ANNX
Último preço
$ 4,020
Variação (24h)
-0,02 USD (0,50%)
Volume
3.28M
Volume (média 4 sem.)
-
Abertura
$ 4,04
Variação do dia
$ 3,95 - $ 4,20
Fechamento anterior
$ 4,04
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
ANNX price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals